1-2 of 2
Michael Kundi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Joshua Tobias, Marina Maglakelidze, Zoran Andrić, Dinara Ryspayeva, Iurie Bulat, Ivan Nikolić, Zoran Petrović, Tanuj Chawla, Rajnish Nagarkar, Erika Garner-Spitzer, Christoph C. Zielinski, Leslie Mi Ok Chong, Bonnie Nixon, Nicholas J. Ede, Sharon Yavrom, Michael Kundi, Ursula Wiedermann
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4044–4054.
https://doi.org/10.1158/1078-0432.CCR-24-0742
Published: 13 September 2024
View article titled, Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Open the PDF for Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON) in another window
Includes: Supplementary data
Journal Articles

Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse

Wolfgang R. Sperr, Margit Mitterbauer, Gerlinde Mitterbauer, Michael Kundi, Ulrich Jäger, Klaus Lechner, Peter Valent
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6536–6543.
https://doi.org/10.1158/1078-0432.CCR-05-0732
Published: 15 September 2005
View article titled, Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse
Open the PDF for Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse in another window